ADHD Stock News 16.23 05/13/2014 16:55:26 Alcobra Ltd (ADHD)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Alcobra Ltd (ADHD) 16.23 $ADHD

Alcobra Ltd. Presents Evidence of Novel Mechanism of Action for Metadoxine Extended Release (MDX) in Cognitive Disorders at the Society of Biological Psychiatry Annual Meeting
GlobeNewswire - Mon May 12, 7:01AM CDT
-- Improvements in cognitive performance in animal models are consistent with MDX effects in human adults with ADHD -

Alcobra Announces FDA Clearance of Protocol for Phase IIb Study of Metadoxine Extended Release (MDX) in the Treatment of Fragile X Syndrome
GlobeNewswire - Thu May 08, 11:21AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine Extended Release (MDX), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, today announced that FDA has approved the protocol for the Company's planned Phase IIb clinical trial of MDX for the treatment of Fragile X Syndrome. The trial is expected to begin enrolling patients shortly.

Alcobra Ltd. to Provide Corporate Overview at Oppenheimer and BioMed Conferences
GlobeNewswire - Thu May 08, 7:02AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that Dr. Yaron Daniely, President and Chief Executive Officer of Alcobra, will provide a corporate overview at two Israeli conferences in May, 2014.

Alcobra Ltd. to Release First Quarter 2014 Results and Host Investor Conference Call on Thursday, May 15, 2014
GlobeNewswire - Wed May 07, 3:46PM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its financial results for the first quarter of 2014 and will host a corporate update conference call on Thursday, May 15, 2014.

Alcobra Ltd. Presents Positive Results From Phase IIb Study of Metadoxine Extended Release (MDX) in Adults With Predominantly Inattentive ADHD at APA Annual Meeting
GlobeNewswire - Mon May 05, 8:41AM CDT
-- MDX produced statistically significant improvement (p < 0.01) on the primary endpoint compared to placebo

Alcobra Issued New US Patent Covering Metadoxine Use for Cognitive Disorders
GlobeNewswire - Thu May 01, 7:13AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine Extended Release (MDX), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, today announced that the United States Patent and Trademark Office ("USPTO" has issued a new patent covering MDX's use in the treatment of Cognitive Disorders.

Alcobra Ltd. to Present New Data for Metadoxine Extended Release (MDX) at Upcoming Meetings
GlobeNewswire - Thu Apr 24, 7:01AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, will present new data for Metadoxine Extended Release (MDX or MG01CI) at the upcoming 167 Annual Meeting of the American Psychiatric Association (APA) and 69 Annual Scientific Meeting of the Society of Biological Psychiatry (SOBP), both held in New York, NY. Details of the presentations are as follows:

Alcobra Ltd. Submits Protocol to FDA for Phase IIb Clinical Study of Metadoxine Extended Release (MDX) in the Treatment of Fragile X Syndrome
GlobeNewswire - Thu Apr 10, 11:30AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine Extended Release (MDX), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, today announced that it has submitted a protocol to the FDA for a Phase IIb clinical trial for its MDX product candidate for the treatment of patients with Fragile X Syndrome.

Alcobra Announces Shares Uplisted to NASDAQ Global Market
GlobeNewswire - Wed Mar 26, 7:00AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine Extended Release (MDX), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, announced today that its stock has been approved to list on the Nasdaq Global Market, effective with the open of the stock market on Friday, March 28, 2014. Until the stock is transferred to Nasdaq Global Market, ADHD's stock will continue to trade on the Nasdaq Capital Market. The company will continue to trade under its existing ticker symbol "ADHD."

Pipeline Update from Alcobra - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 24, 11:10AM CDT
Alcobra enrolled the first patient in a randomized, placebo-controlled phase III study on metadoxine extended release (MDX) for attention deficit hyperactivity disorder (ADHD).

Today’s Top Biotech Stories: Prosensa, Medivation, and Alcobra
Leo Sun, The Motley Fool - Motley Fool - Tue Mar 18, 8:26AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at this three top stocks -- Prosensa , ...

Alcobra Announces Enrollment of First Patient in Phase 3 Clinical Trial for MDX in Adult ADHD
GlobeNewswire - Tue Mar 18, 7:00AM CDT
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine Extended Release (MDX), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, announced today that, following the recent FDA acceptance of the Company's IND for MDX, the first patient has been enrolled in a Phase 3 clinical trial of MDX in the treatment of Adults with ADHD.

Alcobra Gains IND Clearance for MDX - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 5:40PM CST
Alcobra's IND application for Metadoxine Extended Release (MDX) has been cleared by the U.S. FDA recently.

Alcobra Announces FDA Clearance of IND for Metadoxine Extended Release (MDX)
GlobeNewswire - Fri Mar 07, 2:57AM CST
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine Extended Release (MDX) to treat cognitive dysfunctions, such as Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, announced today that the US. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for MDX. This step will allow for the initiation of US clinical trials.

Alcobra (ADHD) Jumps: Stock Rises 8.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 8:04AM CST
Alcobra Ltd. was a big mover last session, as the company saw its shares rise by over 8% on the day.

Alcobra Ltd. to Discuss Biomarkers in Fragile X and Autism Trials at the Second Annual Autism Investment Conference
GlobeNewswire - Mon Feb 24, 7:08AM CST
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate Metadoxine extended-release (MDX), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, today announced that Dr. Jonathan Rubin, Chief Medical Officer of Alcobra, will give a presentation entitled, "The Use of Biomarkers in Fragile X and Autism Clinical Trials," at Autism Speaks' Autism Investment Conference, being held at the Bently Reserve Banking Hall in San Francisco on March 4-5, 2014. The Alcobra presentation is on Tuesday, March 4, during the "Medicines and Therapeutic Devices" session.

Alcobra Appoints J.P. Morgan Banker Dr. Tomer Berkovitz as Chief Financial Officer
GlobeNewswire - Wed Feb 19, 7:00AM CST
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate, Metadoxine Extended Release (MDX; MG01CI), to treat cognitive dysfunction, announced today that it has appointed Dr. Tomer Berkovitz as Chief Financial Officer, effective May 1, 2014. Dr. Berkovitz will report to Dr. Yaron Daniely, President and Chief Executive Officer, and will be responsible for all Corporate Finance and Accounting activities for Alcobra.

Alcobra Announces Fourth Quarter and Fiscal Year End 2013 Financial Results and Corporate Update
GlobeNewswire - Thu Feb 13, 7:00AM CST
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate, MG01CI (Metadoxine extended-release), to treat cognitive dysfunctions, such as Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced its financial results for the quarter and year-ended December 31, 2013.

Alcobra Ltd submits IND to US FDA for Phase III development programme of MG01CI in adults with ADHD
M2 - Mon Feb 10, 6:55AM CST
Biopharmaceutical company Alcobra Ltd (NasdaqCM:ADHD) said on Friday that it has filed an Investigational New Drug Application (IND) with the US Food and Drug Administration (FDA) to initiate a Phase III clinical trial with MG01CI.

Alcobra Announces IND Submission for Extended Release Metadoxine to Treat Adults With ADHD
GlobeNewswire - Fri Feb 07, 12:59PM CST
Alcobra Ltd. (Nasdaq:ADHD), an emerging biopharmaceutical company primarily focused on the development and commercialization of its proprietary drug candidate, MG01CI (Metadoxine extended-release), to treat cognitive dysfunctions, such as ADHD and Fragile X Syndrome, today announced the submission of an Investigational New Drug Application (IND) with the U.S. Food and Drug Administration (FDA) to initiate a Phase III clinical trial with MG01CI. The study is entitled "A 6-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg Compared with Placebo in Adults with Attention Deficit/Hyperactivity Disorder (ADHD)."
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Visit W&H at the Greater New York Dental Meeting

Updated Category News Views 89

Why This Event Matters for Dental Professionals Stroll through any convention center halls and you can see the future unfolding right in front of you. The upcoming Greater New York Dental Meeting is no different, especially with W&H Group setting up shop. For any dental professionals out there, this is your chance to get your hands on some real-deal tech that might just...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 168

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 113

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
SiteOne Joins S&P SmallCap 600 Amid KKR's Integer Buyout

Updated Category News Views 99

Changes on the SmallCap Horizon Starting off, SiteOne Landscape Supply (NYSE: SITE) is hopping onto the S&P SmallCap 600 bandwagon. This shift activates just as the market revs up on November 19, 2026. SiteOne is stepping in as Integer Holdings Corp. (NYSE: ITGR) makes its grand exit, a move prompted by a significant acquisition by KKR & Co. Inc. (NYSE: KKR). KKR’s...

Continue Reading
Terminus Ballet: A Decade of Defying Dance Norms

Updated Category News Views 183

A Dance Company's Journey of Transformation An anniversary represents more than just a celebration; it's a reminder of the road traveled. On Jan. 30, 2027, Terminus Modern Ballet Theatre will mark its 10th anniversary, encapsulating a decade of defiance against the staid conventions binding classical ballet. This isn't just about pirouettes and pliés—it's dance with a...

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 149

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 150

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
Chicago Auto Show: Run & Explore Indoors This February

Updated Category News Views 136

Nobody’s thinking about running laps when they walk into a colossal auto show, but the Chicago Auto Show isn't letting the pedal ease off the gas. Swing by on February 14, folks, for something not typically seen on the floors of McCormick Place. Run participants have got one hour to log as many miles as they can on the 2.4-mile loop right inside the show. Why a Running...

Continue Reading
Insight Into Midland TX Real Estate Sales Timing

Updated Category News Views 46

How Fast Do Homes Move in Midland? This ain't my first rodeo predicting the real estate rollercoaster in Texas. Midland's housing market is one nifty beast—homes can either sell like hotcakes or just sit gathering dust. You got HelloNation pulling in DeLaura Gammage, a pro who knows the terrain like the back of her hand, to spell out the why and how long it'll take to...

Continue Reading
Loyalty Programs Cut $1500 Annually for Consumers

Updated Category News Views 122

Loyalty Programs: An Essential Tool for Households In a world where every dollar counts, retail loyalty programs have become more than just a marketing strategy—they're lifelines for American households scraping through each month. According to fresh research by the Retail Industry Leaders Association (RILA) and conducted by market research leader Circana, these...

Continue Reading

Top 5 Most Recently Viewed Articles

Chuyuan Group's Transformative Journey Towards Sustainable Success

Updated Category News Views 226

Chuyuan Group's Path to Sustainability and Growth In recent years, Chuyuan Group has significantly transformed its operations, embracing high-quality development in response to the evolving regulatory landscape. As the industry landscape changes, companies like Chuyuan must adapt to remain competitive and environmentally responsible. Understanding the Shift: Old Yang and...

Continue Reading
Adani Bonds Face Downgrade Risk Amid U.S. Bribery Scandal

Updated Category News Views 355

Fitch Ratings Puts Adani Group Bonds on Negative Watch In a significant move, Fitch Ratings has placed bonds from various units of the Adani Group on a watchlist for potential downgrades. This action follows serious allegations against the conglomerate's top executives, who are facing U.S. charges related to bribery and fraud. Implications of the Watch Status Fitch's...

Continue Reading
Investigation of Arbor Realty Trust: What Investors Should Know

Updated Category News Views 81

Understanding the Investigation of Arbor Realty Trust Faruqi & Faruqi, LLP, a well-known national securities law firm, is currently looking into claims related to Arbor Realty Trust, Inc. (NYSE: ABR). Investors who have suffered losses exceeding $100,000 while investing in Arbor are encouraged to get in touch for more information and support. Who Should Reach Out to...

Continue Reading
Qualcomm's Strategic Move: Potential Intel Acquisition Talks

Updated Category News Views 185

Qualcomm's Interest in Intel's Assets Recently, Qualcomm has made headlines by showing interest in buying parts of Intel. This move seems to be a strategic effort by Qualcomm to strengthen its presence in the competitive technology market, especially within the chip manufacturing sector. Shifting Market Dynamics Intel, a leader in chip production, is currently facing...

Continue Reading
Refined Energy Corp Expands Partnership with Eagle Plains Resources

Updated Category News Views 113

Refined Energy Corp Strengthens Its Partnership Refined Energy Corp announces an important amendment to its agreement with Eagle Plains Resources Ltd. The key focus of this amendment is to enhance their collaboration on the Dufferin Project, a project located in Canada's Athabasca Basin, known for its rich mineral deposits. Details of the Amended Agreement In a recent...

Continue Reading